Timing, Selection, Modulation, and Duration of P2Y<sub>12</sub> Inhibitors for Patients With Acute Coronary Syndromes Undergoing PCI (JACC Cardiovascular Interventions January 2023)

Timing, Selection, Modulation, and Duration of P2Y₁₂ Inhibitors for Patients With Acute Coronary Syndromes Undergoing PCI (JACC Cardiovascular Interventions January 2023)

Description

Dual antiplatelet therapy with aspirin and the oral P2Y₁₂ inhibitor clopidogrel as the cornerstone of treatment for patients with an acute coronary syndrome (ACS) undergoing percutaneous coronary intervention (PCI) was firstly established in 2001.

Editors

JACC: Cardiovascular Interventions Editor-in-Chief
David J. Moliterno, MD, FACC

JACC: Cardiovascular Interventions CME/MOC/ECME Editor
Michael C. McDaniel, MD

Authors
Davide Capodanno, MD
Dominick J. Angiolillo, MD, PHD

Important Dates

Date of Release: January 9, 2023
Term of Approval/Date of CME/MOC Expiration: January 8, 2024

Summary


Availability:	Retired


Cost:	FREE


Credit Offered:	No Credit Offered